Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease to affect Caucasian populations. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) result in reduced expression and function of the CFTR with the most common mutation (ΔF508/ΔF508) resulting in inadequate processing of the protein and subsequent intracellular trapping in the endoplasmic reticulum (ER) (Elborn, 2016). Clinical manifestations of this debilitating condition include repeated pulmonary infections, innate immune-driven episodes of inflammation and inflammatory arthritis (Elborn, 2016; Whitsett and Alenghat, 2015; Bals et al., 1999; Montgomery et al., 2017). The CFTR protein is widely expressed in a variety of cells and tissues where it functions as an anion channel, conducting chloride (Cl^-) and bicarbonate (HCO3-) ions, and as a regulator of a range of epithelial transport proteins, including the epithelial sodium channel (ENaC) (König et al., 2002; Konstas et al., 2003; Kunzelmann, 2003; Berdiev et al., 2009).

The NLRP3 inflammasome is an important inflammatory pathway in CF but there is little indication as to whether this reflects underlying innate autoinflammation or activation in response to chronic bacterial, viral and fungal infections, including pathogens such as Pseudomonas aeruginosa, and Burhkholderia cepacia complex (Iannitti et al., 2016; Rimessi et al., 2015; Montgomery et al., 2017; Fritzsching et al., 2015; Kiedrowski and Bomberger, 2018). We propose that CF exhibits many hallmarks of an autoinflammatory condition (Peckham et al., 2017; McGonagle and McDermott, 2006; McDermott et al., 1999), with infiltration by innate immune cells (macrophages and neutrophils) at target sites, and a lack of autoantibodies or autoreactive T cells (McDermott et al., 1999). The NLRP3 intracellular protein complex is a sensor that detects changes in cellular homeostasis rather than directly sensing common pathogenic or endogenous motifs. Multiple cellular events have been observed to trigger NLRP3 activation, including K⁺ efflux, Na⁺ influx, Cl^- efflux and Ca²⁺ signalling (Schorn et al., 2011; Muñoz-Planillo et al., 2013; Katsnelson and George, 2013; Domingo-Fernández et al., 2017; Green et al., 2018; Hafner-Bratkovič and Pelegrín, 2018). All known canonical inflammasomes, including the NLRP3 inflammasome, function as signalling platforms for caspase-1-driven activation of IL-1-type cytokines (IL-1β and IL-18). One of IL-18’s main functions is induction of cell-mediated immunity and IFN-γ secretion by natural killer (NK) and T-cells, whereas IL-1β has a central role in inducing fever with immune cell proliferation, differentiation and apoptosis. Inflammasome activation induces a programmed cell death downstream of the activation of caspases-1, 4, 5, and 11. Gasdermin D (GSDMD) is cleaved by said caspases, oligomerizing and forming pores (13 nm) in the plasma membrane, releasing mature IL-1β and IL-18 and triggering cell lysis, or pyroptosis (Cookson and Brennan, 2001; Platnich and Muruve, 2019).

In healthy lungs, ENaC helps maintain normal volume and composition of airway surface liquid (ASL). An absence or reduction in functional CFTR leads to defective CFTR-mediated anion transport and upregulation of ENaC. These changes in normal homeostasis result in fluid hyperabsorption, abnormally thick viscous mucus and defective mucociliary clearance (Althaus, 2013; Boucher, 2019). While there is no literature to support a direct link between ENaC and inflammation in CF, there is indirect evidence to suggest that aberrant sodium (Na⁺) transport influences the disease process. Overexpression of β-ENaC in mice, results in CF-like lung disease, with ASL dehydration, inflammation and mucous obstruction of bronchial airways (Mall et al., 2004; Zhou et al., 2011; Zhou et al., 2008). In humans, genetic variants in the β- and γ- ENaC chains, leading to functional abnormalities in ENaC, have been associated with bronchiectasis and CF-like symptoms (Fajac et al., 2008). By contrast, rare mutations associated with hypomorphic ENaC activity, can slow disease progression in patients homozygous for the CFTR ∆F508 mutation (Mall et al., 2004; Zhou et al., 2011; Donaldson and Boucher, 2007). These studies highlight the essential role of ENaC in regulating normal airway homeostasis and show that inhibition of ENaC may modify disease progression, either by altering ASL composition or modifying other processes, such as inflammation. Several trials are ongoing to assess the safety and effectiveness of new topical ENaC inhibitors to restoring airway surface liquid and mucociliary clearance in CF (Cystic Fibrosis Foundation, 2017).

The aims of this study were to characterise NLRP3 inflammasome activation in CF and to investigate the role of the epithelial Na⁺ channel, ENaC, in driving this inflammation through alterations in ionic homeostasis, a known NLRP3 activating event.

In order to fulfil these aims, monocytes and epithelial cells with characterised CF-associated mutations are directly compared to cohorts of NCFB and SAID.The NCFB cohort comprises of individuals with primary ciliary dyskinesia (PCD), a rare, ciliopathic, autosomal recessive genetic disorder affects the movement of cilia in the lining of the respiratory tract. Individuals with PCD suffer from reduced mucus clearance from the lungs, and susceptibility to chronic recurrent respiratory infections, as is the case with CF. By comparing monocytic- and epithelial-driven inflammation in CF and PCD, one is able to distinguish between inflammation due to recurrent infection, as is the case with both CF and NCFB, and inflammation that is downstream of CFTR/ENaC-mediated ionic disturbances, specific to CF.

The SAID patient cohort is composed of an array of systemic autoinflammatory diseases that are defined by an innate immune driven inflammation. The variety of autoinflammatory disorders described in this manuscript demonstrates the broad range of pathophysiology within this rare inflammatory disease spectrum. Here we demonstrate that the intrinsic ionic defect in cells and individuals with CF-associated mutations predisposes hyperactivation of the NLRP3 inflammasome, leading to inappropriate and destructive innate immune driven inflammation, as found in autoinflammation.

Here we have described our findings that IL-1-type cytokines were elevated in both monocytes and serum of patients with CF, but two of the major inflammasome-independent cytokines, TNF and IL-6, were not significantly elevated in these patients. In contrast to patients with SAID, these data suggest that the proinflammatory cytokine response in CF has a predominant NLRP3 inflammasome constitution. Furthermore, on NLRP3 inflammasome activation, IL-18 secretion was upregulated in the CF-associated mutant cell lines, IB3-1 (p<0.0001) and CuFi-1 (p<0.0001) relative to the BEAS-2B control, and these levels were reduced by treatment with small molecule inhibition of NLRP3 inflammasome signalling, thereby confirming the NLRP3 inflammasome as a major source of the elevated IL-18 inflammatory cytokine in these cells. Perhaps the most notable feature is the uncovering of a molecular link between enhanced ENaC-dependent Na+ influx, observed in cells with CF-associated mutations, and the exacerbated NLRP3 inflammasome activation. By pretreating these cells with CF-associated mutations with small molecule inhibitors of ENaC, the exaggerated IL-1-type cytokine response in vitro was diminished (Figure 7).

Figure 7

Download asset Open asset

Bronchial epithelial cell (BEC) lines can produce significant quantities of IL-18 on stimulation but secrete only negligible amounts of basal or stimulated IL-1β compared to hematopoietic cells (Tang et al., 2012; Peeters et al., 2013; Gillette et al., 2013). In human BEC models, rhinovirus has been associated with IL-1β release, a process accentuated by dual priming with both ATP and polyinosine polycytidylic acid (Poly I:C, which interacts with TLR3) (Piper et al., 2013; Shi et al., 2012). In general, IL-18 is the predominant cytokine secreted by non-myeloid cells, which are also capable of having activated inflammasomes (Okazawa et al., 2004). This contrasts with PBMCs, which produce large amounts of IL-1β, from both patients with CF and healthy controls (Tang et al., 2012). The differential secretion of IL-18 and IL-1β, observed in this study is noteworthy, with IL-1β secretion being undetectable in HBEC lines, under the conditions used. This disparity may reflect the function of these two inflammasome-processed zymogens; IL-18 is a cytokine that induces recruitment of neutrophils and Th17 differentiation, as well as IFNγ secretion, whereas IL-1β is an intrinsically more destructive cytokine, acting systemically to induce fever, proliferation, differentiation, apoptosis and sensitivity to pain. IL-1β secretion is tightly regulated by a highly controlled process, involving its own gene expression as well as inflammasome priming and assembly, whereas IL-18 is constitutively expressed and only depends on the two signals for inflammasome priming and assembly. In addition, IL-1β is rapidly sequestered, or secretion, by IL-1Ra and soluble IL-1RI and –RII, once secreted, which makes IL-1β particularly difficult to assay and detect. The biological property of IL-1β underlies the severe phenotype of the rare autoinflammatory disease, deficiency of the interleukin-1–receptor antagonist (DIRA), caused by homozygous mutations in the IL1RN gene, which encoding the IL-1Ra protein (Aksentijevich et al., 2009).

The primary consequence of mutations in the CFTR gene is defective CFTR anion transport and upregulation of Na⁺ transport through dysregulation of ENaC (Muraglia et al., 2019; Peckham et al., 1997). Under in vivo conditions, patients with CF have a more negative baseline airway and nasal potential difference compared to HC and shows an enhanced depolarising response to amiloride, reflecting the inhibition of excessive ENaC mediated Na⁺ influx (Solomon et al., 2018). In airway epithelial cells, increased basolateral Na/K-ATPase activity has also been reported (Peckham et al., 1997). We hypothesised that dysregulation of Na⁺ transport might influence NLRP3 inflammasome activation by increasing K⁺ efflux, a principal trigger for NLRP3 activation (Schorn et al., 2011; Muñoz-Planillo et al., 2013; Katsnelson and George, 2013; Katsnelson et al., 2015; Di et al., 2018; Qu et al., 2017; Zhu et al., 2017; Rivers-Auty and Brough, 2015). We confirmed a dysregulation of Na⁺ and K⁺ transport by examining primary innate immune cells and HBEC lines with CF-associated mutations in vitro and discovered that excessive ENaC-mediated Na⁺ flux, measured indirectly by dependent changes of fluorescence signal, correlate with an increased K⁺ efflux, an activating signal of the NLRP3 inflammasome and downstream IL-18 and IL-1β secretion. We also show that the systemic serum cytokine signature from patients with CF is comparable to patients diagnosed with SAID, characterised by release of proinflammatory IL-1β and IL-18, which are associated with inflammasome activation. On exploration of the inflammation involved, we found a LPS-induced hyper-responsive NLRP3 inflammasome, exclusively in cells with CF-associated mutations, comparable to monocytes from patients with SAID. It should be noted that the SAID patient cohort is comprised of a variety of autoinflammatory diseases that have differing molecular pathophysiology and varying degrees of innate driven inflammation. This NLRP3 inflammasome activation extended beyond IL-18 and IL-1β secretion, with increased propensity for pyroptotic cell death and associated release of NLRP3 inflammasome components, such as ASC, and induction of IFN-γ secretion in the PBMC population. This type of inflammation has similarities to autoinflammation, particularly the IL-1/IL-18 inflammasome signature observed in serum and also present in vitro. The significantly elevated levels of ASC specks in CF sera (Figure 3D), in addition to the proinflammatory IL-1-type cytokine signature (Figure 3A–C), suggests the presence of a NLRP3 inflammasome agonist. A wide range of possible candidates for such an agonist(s) include infectious pathogens (either CF or non-CF related), the patients’ metabolic milieu or, indeed, other unknown agonists. Further work will be necessary to decipher the complex molecular mechanisms involved. This study does not suggest that inflammation is independent of infections in individuals with CF but that the response to said infections is intrinsically dysregulated and predisposed to excessive and inappropriate degrees of inflammation.

Cystic fibrosis is a monogenic disease, yet consists of varying degrees of pathology depending on the precise CFTR mutation and the extent to which the encoded CFTR protein is subsequently transcribed, translated, folded within the ER, expressed on the plasma membrane, its stability on the surface and its ability to conduct chloride and bicarbonate. There are well documented examples of different classes of CFTR mutations that fail at each one of the above stages of CFTR expression and function. The IB3-1 (ΔF508/W1282X) cell line is associated with the greatest amounts of inflammation. The W1282X mutation is associated with severe disease clinically, that can be attributed to little to no protein expression. Inflammation in the IB3-1 cell line in vitro does not correlate with ENaC protein expression. The underlying mechanism of an ENaC/NLRP3 axis driving inflammation in cells with CF-associated mutations may not be common to all mutation classes. Notably, all of the cells (monocytes and epithelia) had at least one ΔF508 allele. Whether the loss of control of ENaC expression and function observed in ΔF508 CFTR expressing cells is unique to this more common mutation will require further study. It is important to note that inhibition of ENaC alleviated NLRP3 inflammasome-mediated inflammation in all cell lines (Figure 5E–F). While inflammation in CF is believed to be driven predominantly by infection, many CFTR mutant animal models have shown that airway inflammation and bronchiectasis can occur under sterile conditions (Montgomery et al., 2017; Keiser et al., 2015; Rao and Grigg, 2006). For instance, in a CFTR knockout ferret model, inflammation, bronchiectasis and mucus accumulation can develop in the absence of infection (Rosenow, 2018). A recent study from the Australian Respiratory Early Surveillance Team for CF highlights the association between pulmonary inflammation and structural lung disease in young children with and without infection (Rosenow et al., 2019). IL-1β is detectable in bronchoalveolar lavage (BAL) fluid from children with CF and is strongly correlated with neutrophil counts, independent from detectable infection (Montgomery et al., 2018). The increased IL-1β neutrophil production in BAL fluid from patients with CF appears to be driven via NLRP3 (McElvaney et al., 2018).

Autoinflammation is defined as an exaggerated inflammatory response, driven by dysregulated innate immune cells, in the absene of antigen-driven T-cells, B-cells, or associated autoantibodies (Peckham et al., 2017; McDermott et al., 1999; McDermott and Aksentijevich, 2002; McGonagle and McDermott, 2006; Stoffels and Kastner, 2016). Adaptive immune cells may be recruited in response to the downstream consequences of autoinflammation, with increased susceptibility to infection, and progression to autoimmunity and hyperinflammation (Wekell et al., 2016). In fact, we have shown that endoplasmic reticulum (ER) stress present in CF innate immune cells, including neutrophils, monocytes and M1 macrophages, causes an exaggerated inflammatory response (Lara-Reyna et al., 2019). Based on these data and cited literature, CF displays features of autoinflammatory disease, in part driven by aberrant ionic fluxes and recurrent infections. The NLRP3 inflammasome can be primed by proinflammatory cytokines, such as TNF, although bacterial components do provide a far more potent stimulus (Swanson et al., 2019; McElvaney et al., 2019).

Targeting the exaggerated inflammatory response without simultaneously predisposing individuals to infection remains an elusive goal which carries inherent (potential) risk. This was highlighted by the termination of a study investigating a leukotriene B_4- (LTB₄) receptor antagonist for treatment of lung disease in CF following a disproportionate incidence of respiratory serious adverse events (Konstan et al., 2014). Treating inflammation remains a priority and multiple trials targeting various anti-inflammatory pathways are ongoing (Cystic Fibrosis Foundation, 2017). There is evidence in the literature of endotoxin tolerant monocytes from patients with CF, with reduced cytokine expression in response to repetitive endotoxin exposure (del Campo et al., 2011; del Fresno et al., 2009; del Fresno et al., 2008). However, we propose that peripheral monocytes such as those used in this study, are not constantly exposed to common pathogenic antigens that exist within the lung microenvironment during infections. In fact, one may propose a scenario of trained immunity, where innate immune cells hyper-respond to the recurrent infections with greater destructive consequences. Endotoxins are not the only inflammatory stimulus for NLRP3 inflammasome priming that exist in the inflammatory milieu of the CF lung. Epithelial derived cytokines, neutrophilic extracellular traps (NETs), necrotic cell death and subsequent damage associated molecular patterens (DAMPs) may all induce transcription of IL-1β/IL-18 and other inflammasome components, independent of endotoxins. A caveat of our study is that we have not tested the full array of DAMPs and pathogen associated molecular patterns (PAMPs) that exist in the CF lung that may trigger the intrinsic predisposition to NLRP3 inflammasome activation observed in this study.

The data here suggest that IL-18 may be a useful therapeutic target, by preventing adaptive cell airway infiltration whilst maintaining a potent IL-1β response to infection (Gabay et al., 2018); however, NLRP3 activation exercises a protective role in animal models of induced colitis (Allen et al., 2010), running contrary to the expectation that reduced NLRP3 expression might reduce inflammation in the bowel. Furthermore, IL-18 has an epithelial protective role in promoting repair of gut epithelium (Zaki et al., 2010), and more ex vivo studies and CF disease models are required to elucidate the benefits or hazards of IL-18 blockade. Anakinra is a viable therapeutic option for CF, particularly with its short half-life and daily treatment regime allowing a more controlled dosage during any inevitable infections. In fact a phase IIa clinical trial to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis is in progress (EudraCT Number: 2016-004786-80). It is notable that inhibition of TLR4 signalling was the most effective means of blocking NLRP3 activation in our study, which suggests that targeting this pathway may be a therapeutic option in CF (Keeler et al., 2019; Greene et al., 2008). These novel data, along with our observation that decreased intracellular K⁺ levels upon stimulation with ATP in cells with CF-associated mutations, correlates with the characteristic and excessive ENaC-mediated Na⁺ transport, suggest that CF-associated mutations lower the threshold for NLRP3 assembly, rather than priming this key intracellular component of innate immune defenses.

Through inhibition of amiloride-sensitive Na⁺ channels, we were able to reduce NLRP3 inflammasome activation, and associated IL-18 and IL-1β secretion, in vitro. Notably, ENaC inhibition did not modulate IL-18 and IL-1β secretion in monocytes from individuals with SAID, indicating the proposed ENaC-NLRP3 axis is unique to CF-associated mutations. These findings highlight the importance of excessive ENaC-mediated intracellular Na⁺ as a disease mechanism in CF, and also highlight its potential as a therapeutic target. Targeting amiloride-sensitive Na⁺ channels such as ENaC to restoring airway surface liquid and mucociliary clearance, has been previously attempted, using amiloride in the 1990 s, with little efficacy, due to amiloride’s short half-life and limited effectiveness (Graham et al., 1993).

In conclusion, we have shown that hypersensitive NLRP3 inflammasome activation in CF induces proinflammatory serum and cellular profiles. Overexpression of β-ENaC, in the absence of CFTR dysfunction as well as dysregulation of amiloride-sensitive Na⁺ channel activity in CF, further potentiates LPS-induced NLRP3 inflammasome activity. Both ENaC and NLRP3 are potential therapeutic targets for reducing inflammation in patients with CF.

All data generated or analysed during this study are included in the manuscript and supporting files.

1. 1. Aksentijevich I
   2. Masters SL
   3. Ferguson PJ
   4. Dancey P
   5. Frenkel J
   6. van Royen-Kerkhoff A
   7. Laxer R
   8. Tedgård U
   9. Cowen EW
   10. Pham TH
   11. Booty M
   12. Estes JD
   13. Sandler NG
   14. Plass N
   15. Stone DL
   16. Turner ML
   17. Hill S
   18. Butman JA
   19. Schneider R
   20. Babyn P
   21. El-Shanti HI
   22. Pope E
   23. Barron K
   24. Bing X
   25. Laurence A
   26. Lee CC
   27. Chapelle D
   28. Clarke GI
   29. Ohson K
   30. Nicholson M
   31. Gadina M
   32. Yang B
   33. Korman BD
   34. Gregersen PK
   35. van Hagen PM
   36. Hak AE
   37. Huizing M
   38. Rahman P
   39. Douek DC
   40. Remmers EF
   41. Kastner DL
   42. Goldbach-Mansky R

   (2009) An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist

   New England Journal of Medicine 360:2426–2437.

   https://doi.org/10.1056/NEJMoa0807865

   • PubMed
   • Google Scholar
2. 1. Allen IC
   2. TeKippe EM
   3. Woodford RM
   4. Uronis JM
   5. Holl EK
   6. Rogers AB
   7. Herfarth HH
   8. Jobin C
   9. Ting JP

   (2010) The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated Cancer

   The Journal of Experimental Medicine 207:1045–1056.

   https://doi.org/10.1084/jem.20100050

   • PubMed
   • Google Scholar
3. 1. Althaus M

   (2013) ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art

   Current Molecular Pharmacology 6:3–12.

   https://doi.org/10.2174/18744672112059990025

   • PubMed
   • Google Scholar
4. 1. Bals R
   2. Weiner DJ
   3. Wilson JM

   (1999) The innate immune system in cystic fibrosis lung disease

   Journal of Clinical Investigation 103:303–307.

   https://doi.org/10.1172/JCI6277

   • PubMed
   • Google Scholar
5. 1. Berdiev BK
   2. Qadri YJ
   3. Benos DJ

   (2009) Assessment of the CFTR and ENaC association

   Mol. BioSyst. 5:123–127.

   https://doi.org/10.1039/B810471A

   • PubMed
   • Google Scholar
6. 1. Bergsbaken T
   2. Fink SL
   3. Cookson BT

   (2009) Pyroptosis: host cell death and inflammation

   Nature Reviews Microbiology 7:99–109.

   https://doi.org/10.1038/nrmicro2070

   • PubMed
   • Google Scholar
7. 1. Boucher RC

   (2019) Muco-Obstructive lung diseases

   New England Journal of Medicine 380:1941–1953.

   https://doi.org/10.1056/NEJMra1813799

   • PubMed
   • Google Scholar
8. 1. Cookson BT
   2. Brennan MA

   (2001) Pro-inflammatory programmed cell death

   Trends in Microbiology 9:113–114.

   https://doi.org/10.1016/S0966-842X(00)01936-3

   • PubMed
   • Google Scholar
9. Website

   1. Cystic Fibrosis Foundation

   (2017) Drug developement pipeline

   Accessed May 23, 2017.

   https://www.cff.org/Trials/Pipeline
10. 1. del Campo R
    2. Martínez E
    3. del Fresno C
    4. Alenda R
    5. Gómez-Piña V
    6. Fernández-Ruíz I
    7. Siliceo M
    8. Jurado T
    9. Toledano V
    10. Arnalich F
    11. García-Río F
    12. López-Collazo E

    (2011) Translocated LPS Might Cause Endotoxin Tolerance in Circulating Monocytes of Cystic Fibrosis Patients

    PLOS ONE 6:e29577.

    https://doi.org/10.1371/journal.pone.0029577

    • Google Scholar
11. 1. del Fresno C
    2. Gómez-Piña V
    3. Lores V
    4. Soares-Schanoski A
    5. Fernández-Ruiz I
    6. Rojo B
    7. Alvarez-Sala R
    8. Caballero-Garrido E
    9. García F
    10. Veliz T
    11. Arnalich F
    12. Fuentes-Prior P
    13. García-Río F
    14. López-Collazo E

    (2008) Monocytes from Cystic Fibrosis Patients Are Locked in an LPS Tolerance State: Down-Regulation of TREM-1 as Putative Underlying Mechanism

    PLOS ONE 3:e2667.

    https://doi.org/10.1371/journal.pone.0002667

    • Google Scholar
12. 1. del Fresno C
    2. García-Rio F
    3. Gómez-Piña V
    4. Soares-Schanoski A
    5. Fernández-Ruíz I
    6. Jurado T
    7. Kajiji T
    8. Shu C
    9. Marín E
    10. Gutierrez del Arroyo A
    11. Prados C
    12. Arnalich F
    13. Fuentes-Prior P
    14. Biswas SK
    15. López-Collazo E

    (2009) Potent Phagocytic Activity with Impaired Antigen Presentation Identifying Lipopolysaccharide-Tolerant Human Monocytes: Demonstration in Isolated Monocytes from Cystic Fibrosis Patients

    The Journal of Immunology 182:6494–6507.

    https://doi.org/10.4049/jimmunol.0803350

    • Google Scholar
13. 1. Di A
    2. Xiong S
    3. Ye Z
    4. Malireddi RKS
    5. Kometani S
    6. Zhong M
    7. Mittal M
    8. Hong Z
    9. Kanneganti T-D
    10. Rehman J
    11. Malik AB

    (2018) The TWIK2 potassium efflux channel in macrophages mediates NLRP3 Inflammasome-Induced inflammation

    Immunity 49:56–65.

    https://doi.org/10.1016/j.immuni.2018.04.032

    • Google Scholar
14. 1. Domingo-Fernández R
    2. Coll RC
    3. Kearney J
    4. Breit S
    5. O'Neill LAJ

    (2017) The intracellular chloride channel proteins CLIC1 and CLIC4 induce IL-1β transcription and activate the NLRP3 inflammasome

    Journal of Biological Chemistry 292:12077–12087.

    https://doi.org/10.1074/jbc.M117.797126

    • PubMed
    • Google Scholar
15. 1. Donaldson SH
    2. Boucher RC

    (2007) Sodium channels and cystic fibrosis

    Chest 132:1631–1636.

    https://doi.org/10.1378/chest.07-0288

    • PubMed
    • Google Scholar
16. 1. Elborn JS

    (2016) Cystic fibrosis

    The Lancet 388:2519–2531.

    https://doi.org/10.1016/S0140-6736(16)00576-6

    • Google Scholar
17. 1. Fajac I
    2. Viel M
    3. Sublemontier S
    4. Hubert D
    5. Bienvenu T

    (2008) Could a defective epithelial sodium channel lead to bronchiectasis

    Respiratory Research 9:46.

    https://doi.org/10.1186/1465-9921-9-46

    • PubMed
    • Google Scholar
18. 1. Franklin BS
    2. Bossaller L
    3. De Nardo D
    4. Ratter JM
    5. Stutz A
    6. Engels G
    7. Brenker C
    8. Nordhoff M
    9. Mirandola SR
    10. Al-Amoudi A
    11. Mangan MS
    12. Zimmer S
    13. Monks BG
    14. Fricke M
    15. Schmidt RE
    16. Espevik T
    17. Jones B
    18. Jarnicki AG
    19. Hansbro PM
    20. Busto P
    21. Marshak-Rothstein A
    22. Hornemann S
    23. Aguzzi A
    24. Kastenmüller W
    25. Latz E

    (2014) The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation

    Nature Immunology 15:727–737.

    https://doi.org/10.1038/ni.2913

    • PubMed
    • Google Scholar
19. 1. Fritzsching B
    2. Zhou-Suckow Z
    3. Trojanek JB
    4. Schubert SC
    5. Schatterny J
    6. Hirtz S
    7. Agrawal R
    8. Muley T
    9. Kahn N
    10. Sticht C
    11. Gunkel N
    12. Welte T
    13. Randell SH
    14. Länger F
    15. Schnabel P
    16. Herth FJ
    17. Mall MA

    (2015) Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung disease

    American Journal of Respiratory and Critical Care Medicine 191:902–913.

    https://doi.org/10.1164/rccm.201409-1610OC

    • PubMed
    • Google Scholar
20. 1. Gabay C
    2. Fautrel B
    3. Rech J
    4. Spertini F
    5. Feist E
    6. Kötter I
    7. Hachulla E
    8. Morel J
    9. Schaeverbeke T
    10. Hamidou MA
    11. Martin T
    12. Hellmich B
    13. Lamprecht P
    14. Schulze-Koops H
    15. Courvoisier DS
    16. Sleight A
    17. Schiffrin EJ

    (2018) Open-label, Multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset still’s disease

    Annals of the Rheumatic Diseases 13:840.

    https://doi.org/10.1136/annrheumdis-2017-212608

    • Google Scholar
21. 1. Gillette DD
    2. Shah PA
    3. Cremer T
    4. Gavrilin MA
    5. Besecker BY
    6. Sarkar A
    7. Knoell DL
    8. Cormet-Boyaka E
    9. Wewers MD
    10. Butchar JP
    11. Tridandapani S

    (2013) Analysis of human bronchial epithelial cell proinflammatory response to Burkholderia cenocepacia infection: inability to secrete il-1β

    The Journal of Biological Chemistry 288:3691–3695.

    https://doi.org/10.1074/jbc.C112.430298

    • PubMed
    • Google Scholar
22. 1. Graham A
    2. Hasani A
    3. Alton EW
    4. Martin GP
    5. Marriott C
    6. Hodson ME
    7. Clarke SW
    8. Geddes DM

    (1993)

    No added benefit from nebulized amiloride in patients with cystic fibrosis

    The European Respiratory Journal 6:1243–1248.

    • PubMed
    • Google Scholar
23. 1. Green JP
    2. Yu S
    3. Martín-Sánchez F
    4. Pelegrin P
    5. Lopez-Castejon G
    6. Lawrence CB
    7. Brough D

    (2018) Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming

    PNAS 115:E9371–E9380.

    https://doi.org/10.1073/pnas.1812744115

    • PubMed
    • Google Scholar
24. 1. Greene CM
    2. Branagan P
    3. McElvaney NG

    (2008) Toll-like receptors as therapeutic targets in cystic fibrosis

    Expert Opinion on Therapeutic Targets 12:1481–1495.

    https://doi.org/10.1517/14728220802515293

    • PubMed
    • Google Scholar
25. 1. Hafner-Bratkovič I
    2. Pelegrín P

    (2018) Ion homeostasis and ion channels in NLRP3 inflammasome activation and regulation

    Current Opinion in Immunology 52:8–17.

    https://doi.org/10.1016/j.coi.2018.03.010

    • PubMed
    • Google Scholar
26. 1. Iannitti RG
    2. Napolioni V
    3. Oikonomou V
    4. De Luca A
    5. Galosi C
    6. Pariano M
    7. Massi-Benedetti C
    8. Borghi M
    9. Puccetti M
    10. Lucidi V
    11. Colombo C
    12. Fiscarelli E
    13. Lass-Flörl C
    14. Majo F
    15. Cariani L
    16. Russo M
    17. Porcaro L
    18. Ricciotti G
    19. Ellemunter H
    20. Ratclif L
    21. De Benedictis FM
    22. Talesa VN
    23. Dinarello CA
    24. van de Veerdonk FL
    25. Romani L

    (2016) IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis

    Nature Communications 7:10791.

    https://doi.org/10.1038/ncomms10791

    • PubMed
    • Google Scholar
27. 1. Katsnelson MA
    2. Rucker LG
    3. Russo HM
    4. Dubyak GR

    (2015) K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling

    Journal of Immunology 194:3937–3952.

    https://doi.org/10.4049/jimmunol.1402658

    • PubMed
    • Google Scholar
28. 1. Katsnelson M
    2. George D

    (2013)

    Cytosolic K+ and extracellular na+ as regulators of NLRP3 inflammasome activation and the IL-1β secretion response of macrophages to crystalline stimuli

    The FASEB Journal 27:138.8.

    • Google Scholar
29. 1. Keeler D
    2. Grandal M
    3. McCall J

    (2019) Brevenal, a marine natural product, is Anti-Inflammatory and an immunomodulator of macrophage and lung epithelial cells

    Marine Drugs 17:184.

    https://doi.org/10.3390/md17030184

    • Google Scholar
30. 1. Keiser NW
    2. Birket SE
    3. Evans IA
    4. Tyler SR
    5. Crooke AK
    6. Sun X
    7. Zhou W
    8. Nellis JR
    9. Stroebele EK
    10. Chu KK
    11. Tearney GJ
    12. Stevens MJ
    13. Harris JK
    14. Rowe SM
    15. Engelhardt JF

    (2015) Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs

    American Journal of Respiratory Cell and Molecular Biology 52:683–694.

    https://doi.org/10.1165/rcmb.2014-0250OC

    • PubMed
    • Google Scholar
31. 1. Kiedrowski MR
    2. Bomberger JM

    (2018) Viral-Bacterial Co-infections in the cystic fibrosis respiratory tract

    Frontiers in Immunology 9:3067.

    https://doi.org/10.3389/fimmu.2018.03067

    • PubMed
    • Google Scholar
32. 1. Kim ML
    2. Chae JJ
    3. Park YH
    4. De Nardo D
    5. Stirzaker RA
    6. Ko HJ
    7. Tye H
    8. Cengia L
    9. DiRago L
    10. Metcalf D
    11. Roberts AW
    12. Kastner DL
    13. Lew AM
    14. Lyras D
    15. Kile BT
    16. Croker BA
    17. Masters SL

    (2015) Aberrant actin depolymerization triggers the pyrin inflammasome and autoinflammatory disease that is dependent on IL-18, not IL-1β

    The Journal of Experimental Medicine 212:927–938.

    https://doi.org/10.1084/jem.20142384

    • PubMed
    • Google Scholar
33. 1. König J
    2. Schreiber R
    3. Mall M
    4. Kunzelmann K

    (2002) No evidence for inhibition of ENaC through CFTR-mediated release of ATP

    Biochimica Et Biophysica Acta (BBA) - Biomembranes 1565:17–28.

    https://doi.org/10.1016/S0005-2736(02)00502-3

    • Google Scholar
34. 1. Konstan MW
    2. Döring G
    3. Heltshe SL
    4. Lands LC
    5. Hilliard KA
    6. Koker P
    7. Bhattacharya S
    8. Staab A
    9. Hamilton A
    10. Investigators and Coordinators of BI Trial 543.45

    (2014) A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis

    Journal of Cystic Fibrosis 13:148–155.

    https://doi.org/10.1016/j.jcf.2013.12.009

    • PubMed
    • Google Scholar
35. 1. Konstas A-A
    2. Koch J-P
    3. Korbmacher C

    (2003) cAMP-dependent activation of CFTR inhibits the epithelial sodium channel (ENaC) without affecting its surface expression

    Pflügers Archiv - European Journal of Physiology 445:513–521.

    https://doi.org/10.1007/s00424-002-0957-z

    • Google Scholar
36. 1. Kunzelmann K

    (2003) ENaC is inhibited by an increase in the intracellular cl– concentration mediated through activation of Cl– channels

    Pflügers Archiv - European Journal of Physiology 445:504–512.

    https://doi.org/10.1007/s00424-002-0958-y

    • Google Scholar
37. 1. Lara-Reyna S
    2. Scambler T
    3. Holbrook J
    4. Wong C
    5. Jarosz-Griffiths HH
    6. Martinon F
    7. Savic S
    8. Peckham D
    9. McDermott MF

    (2019) Metabolic reprograming of cystic fibrosis macrophages via the IRE1α arm of the unfolded protein response results in exacerbated inflammation

    Frontiers in Immunology 10:1789.

    https://doi.org/10.3389/fimmu.2019.01789

    • PubMed
    • Google Scholar
38. 1. Mall M
    2. Grubb BR
    3. Harkema JR
    4. O'Neal WK
    5. Boucher RC

    (2004) Increased airway epithelial na+ absorption produces cystic fibrosis-like lung disease in mice

    Nature Medicine 10:487–493.

    https://doi.org/10.1038/nm1028

    • PubMed
    • Google Scholar
39. 1. Mariathasan S
    2. Weiss DS
    3. Newton K
    4. McBride J
    5. O'Rourke K
    6. Roose-Girma M
    7. Lee WP
    8. Weinrauch Y
    9. Monack DM
    10. Dixit VM

    (2006) Cryopyrin activates the inflammasome in response to toxins and ATP

    Nature 440:228–232.

    https://doi.org/10.1038/nature04515

    • PubMed
    • Google Scholar
40. 1. McDermott MF
    2. Aksentijevich I
    3. Galon J
    4. McDermott EM
    5. Ogunkolade BW
    6. Centola M
    7. Mansfield E
    8. Gadina M
    9. Karenko L
    10. Pettersson T
    11. McCarthy J
    12. Frucht DM
    13. Aringer M
    14. Torosyan Y
    15. Teppo AM
    16. Wilson M
    17. Karaarslan HM
    18. Wan Y
    19. Todd I
    20. Wood G
    21. Schlimgen R
    22. Kumarajeewa TR
    23. Cooper SM
    24. Vella JP
    25. Amos CI
    26. Mulley J
    27. Quane KA
    28. Molloy MG
    29. Ranki A
    30. Powell RJ
    31. Hitman GA
    32. O'Shea JJ
    33. Kastner DL

    (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes

    Cell 97:133–144.

    https://doi.org/10.1016/S0092-8674(00)80721-7

    • PubMed
    • Google Scholar
41. 1. McDermott MF
    2. Aksentijevich I

    (2002) The autoinflammatory syndromes

    Current Opinion in Allergy and Clinical Immunology 2:511–516.

    https://doi.org/10.1097/00130832-200212000-00006

    • PubMed
    • Google Scholar
42. 1. McElvaney OJ
    2. Gunaratnam C
    3. O'Neill L
    4. Reeves EP
    5. McElvaney G

    (2018) Metabolic reprogramming of the cystic fibrosis neutrophil drives Interleukin-1β via the NLRP3 inflammasome

    Pediatric Pulmonology 53:S176.

    https://doi.org/10.1002/ppul.24152

    • Google Scholar
43. 1. McElvaney OJ
    2. Zaslona Z
    3. Becker-Flegler K
    4. Palsson-McDermott EM
    5. Boland F
    6. Gunaratnam C
    7. Gulbins E
    8. O'Neill LA
    9. Reeves EP
    10. McElvaney NG

    (2019) Specific inhibition of the NLRP3 inflammasome as an anti-inflammatory strategy in cystic fibrosis

    American Journal of Respiratory and Critical Care Medicine.

    https://doi.org/10.1164/rccm.201905-1013OC

    • PubMed
    • Google Scholar
44. 1. McGonagle D
    2. McDermott MF

    (2006) A proposed classification of the immunological diseases

    PLOS Medicine 3:e297.

    https://doi.org/10.1371/journal.pmed.0030297

    • PubMed
    • Google Scholar
45. 1. Montgomery ST
    2. Mall MA
    3. Kicic A
    4. Stick SM
    5. AREST CF

    (2017) Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies

    European Respiratory Journal 49:1600903.

    https://doi.org/10.1183/13993003.00903-2016

    • PubMed
    • Google Scholar
46. 1. Montgomery ST
    2. Dittrich AS
    3. Garratt LW
    4. Turkovic L
    5. Frey DL
    6. Stick SM
    7. Mall MA
    8. Kicic A
    9. AREST CF

    (2018) Interleukin-1 is associated with inflammation and structural lung disease in young children with cystic fibrosis

    Journal of Cystic Fibrosis 17:715–722.

    https://doi.org/10.1016/j.jcf.2018.05.006

    • PubMed
    • Google Scholar
47. 1. Muñoz-Planillo R
    2. Kuffa P
    3. Martínez-Colón G
    4. Smith BL
    5. Rajendiran TM
    6. Núñez G

    (2013) K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter

    Immunity 38:1142–1153.

    https://doi.org/10.1016/j.immuni.2013.05.016

    • PubMed
    • Google Scholar
48. 1. Muraglia KA
    2. Chorghade RS
    3. Kim BR
    4. Tang XX
    5. Shah VS
    6. Grillo AS
    7. Daniels PN
    8. Cioffi AG
    9. Karp PH
    10. Zhu L
    11. Welsh MJ
    12. Burke MD

    (2019) Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia

    Nature 567:405–408.

    https://doi.org/10.1038/s41586-019-1018-5

    • PubMed
    • Google Scholar
49. 1. Okazawa A
    2. Kanai T
    3. Nakamaru K
    4. Sato T
    5. Inoue N
    6. Ogata H
    7. Iwao Y
    8. Ikeda M
    9. Kawamura T
    10. Makita S
    11. Uraushihara K
    12. Okamoto R
    13. Yamazaki M
    14. Kurimoto M
    15. Ishii H
    16. Watanabe M
    17. Hibi T

    (2004) Human intestinal epithelial cell-derived interleukin (IL)-18, along with IL-2, IL-7 and IL-15, is a potent synergistic factor for the proliferation of intraepithelial lymphocytes

    Clinical and Experimental Immunology 136:269–276.

    https://doi.org/10.1111/j.1365-2249.2004.02431.x

    • PubMed
    • Google Scholar
50. 1. Peckham D
    2. Holland E
    3. Range S
    4. Knox AJ

    (1997) Na+/K+ ATPase in lower airway epithelium from cystic fibrosis and non-cystic-fibrosis lung

    Biochemical and Biophysical Research Communications 232:464–468.

    https://doi.org/10.1006/bbrc.1997.6200

    • PubMed
    • Google Scholar
51. 1. Peckham D
    2. Scambler T
    3. Savic S
    4. McDermott MF

    (2017) The burgeoning field of innate immune-mediated disease and autoinflammation

    The Journal of Pathology 241:123–139.

    https://doi.org/10.1002/path.4812

    • PubMed
    • Google Scholar
52. 1. Peeters PM
    2. Perkins TN
    3. Wouters EF
    4. Mossman BT
    5. Reynaert NL

    (2013) Silica induces NLRP3 inflammasome activation in human lung epithelial cells

    Particle and Fibre Toxicology 10:3.

    https://doi.org/10.1186/1743-8977-10-3

    • PubMed
    • Google Scholar
53. 1. Piper SC
    2. Ferguson J
    3. Kay L
    4. Parker LC
    5. Sabroe I
    6. Sleeman MA
    7. Briend E
    8. Finch DK

    (2013) The role of interleukin-1 and interleukin-18 in pro-inflammatory and anti-viral responses to rhinovirus in primary bronchial epithelial cells

    PLOS ONE 8:e63365.

    https://doi.org/10.1371/journal.pone.0063365

    • PubMed
    • Google Scholar
54. 1. Platnich JM
    2. Muruve DA

    (2019) NOD-like receptors and inflammasomes: a review of their canonical and non-canonical signaling pathways

    Archives of Biochemistry and Biophysics 670:4–14.

    https://doi.org/10.1016/j.abb.2019.02.008

    • PubMed
    • Google Scholar
55. 1. Qu J
    2. Tao XY
    3. Teng P
    4. Zhang Y
    5. Guo CL
    6. Hu L
    7. Qian YN
    8. Jiang CY
    9. Liu WT

    (2017) Blocking ATP-sensitive potassium channel alleviates morphine tolerance by inhibiting HSP70-TLR4-NLRP3-mediated neuroinflammation

    Journal of Neuroinflammation 14:228.

    https://doi.org/10.1186/s12974-017-0997-0

    • PubMed
    • Google Scholar
56. 1. Rao S
    2. Grigg J

    (2006) New insights into pulmonary inflammation in cystic fibrosis

    Archives of Disease in Childhood 91:786–788.

    https://doi.org/10.1136/adc.2004.069419

    • PubMed
    • Google Scholar
57. 1. Rimessi A
    2. Bezzerri V
    3. Patergnani S
    4. Marchi S
    5. Cabrini G
    6. Pinton P

    (2015) Mitochondrial Ca2+-dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa-driven inflammatory response in cystic fibrosis

    Nature Communications 6:6201.

    https://doi.org/10.1038/ncomms7201

    • PubMed
    • Google Scholar
58. 1. Rivers-Auty J
    2. Brough D

    (2015) Potassium efflux fires the canon: potassium efflux as a common trigger for canonical and noncanonical NLRP3 pathways

    European Journal of Immunology 45:2758–2761.

    https://doi.org/10.1002/eji.201545958

    • PubMed
    • Google Scholar
59. 1. Rosenow T

    (2018) Quantification of CT bronchiectasis and its relationship to ventilation in cystic fibrosis

    Thorax 73:4.

    https://doi.org/10.1136/thoraxjnl-2017-210917

    • PubMed
    • Google Scholar
60. 1. Rosenow T
    2. Mok LC
    3. Turkovic L
    4. Berry LJ
    5. Sly PD
    6. Ranganathan S
    7. Tiddens H
    8. Stick SM

    (2019) The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis

    European Respiratory Journal 54:1801771.

    https://doi.org/10.1183/13993003.01771-2018

    • PubMed
    • Google Scholar
61. 1. Rowczenio DM
    2. Pathak S
    3. Arostegui JI
    4. Mensa-Vilaro A
    5. Omoyinmi E
    6. Brogan P
    7. Lipsker D
    8. Scambler T
    9. Owen R
    10. Trojer H
    11. Baginska A
    12. Gillmore JD
    13. Wechalekar AD
    14. Lane T
    15. Williams R
    16. Youngstein T
    17. Hawkins PN
    18. Savic S
    19. Lachmann HJ

    (2018) Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome

    Blood 131:974–981.

    https://doi.org/10.1182/blood-2017-10-810366

    • PubMed
    • Google Scholar
62. 1. Schorn C
    2. Frey B
    3. Lauber K
    4. Janko C
    5. Strysio M
    6. Keppeler H
    7. Gaipl US
    8. Voll RE
    9. Springer E
    10. Munoz LE
    11. Schett G
    12. Herrmann M

    (2011) Sodium overload and water influx activate the NALP3 inflammasome

    Journal of Biological Chemistry 286:35–41.

    https://doi.org/10.1074/jbc.M110.139048

    • PubMed
    • Google Scholar
63. 1. Shi L
    2. Manthei DM
    3. Guadarrama AG
    4. Lenertz LY
    5. Denlinger LC

    (2012) Rhinovirus-induced IL-1β release from bronchial epithelial cells is independent of functional P2X7

    American Journal of Respiratory Cell and Molecular Biology 47:363–371.

    https://doi.org/10.1165/rcmb.2011-0267OC

    • PubMed
    • Google Scholar
64. 1. Solomon GM
    2. Bronsveld I
    3. Hayes K
    4. Wilschanski M
    5. Melotti P
    6. Rowe SM
    7. Sermet-Gaudelus I

    (2018) Standardized measurement of nasal membrane transepithelial potential difference (NPD)

    Journal of Visualized Experiments.

    https://doi.org/10.3791/57006

    • PubMed
    • Google Scholar
65. 1. Stoffels M
    2. Kastner DL

    (2016) Old dogs, new tricks: monogenic autoinflammatory disease unleashed

    Annual Review of Genomics and Human Genetics 17:245–272.

    https://doi.org/10.1146/annurev-genom-090413-025334

    • PubMed
    • Google Scholar
66. 1. Swanson KV
    2. Deng M
    3. Ting JP

    (2019) The NLRP3 inflammasome: molecular activation and regulation to therapeutics

    Nature Reviews Immunology 19:477–489.

    https://doi.org/10.1038/s41577-019-0165-0

    • PubMed
    • Google Scholar
67. 1. Tang A
    2. Sharma A
    3. Jen R
    4. Hirschfeld AF
    5. Chilvers MA
    6. Lavoie PM
    7. Turvey SE

    (2012) Inflammasome-mediated IL-1β production in humans with cystic fibrosis

    PLOS ONE 7:e37689.

    https://doi.org/10.1371/journal.pone.0037689

    • PubMed
    • Google Scholar
68. 1. Venkatakrishnan A
    2. Stecenko AA
    3. King G
    4. Blackwell TR
    5. Brigham KL
    6. Christman JW
    7. Blackwell TS

    (2000) Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells

    American Journal of Respiratory Cell and Molecular Biology 23:396–403.

    https://doi.org/10.1165/ajrcmb.23.3.3949

    • PubMed
    • Google Scholar
69. 1. Wekell P
    2. Karlsson A
    3. Berg S
    4. Fasth A

    (2016) Review of autoinflammatory diseases, with a special focus on periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome

    Acta Paediatrica 105:1140–1151.

    https://doi.org/10.1111/apa.13531

    • PubMed
    • Google Scholar
70. 1. Whitsett JA
    2. Alenghat T

    (2015) Respiratory epithelial cells orchestrate pulmonary innate immunity

    Nature Immunology 16:27–35.

    https://doi.org/10.1038/ni.3045

    • PubMed
    • Google Scholar
71. 1. Zaki MH
    2. Vogel P
    3. Body-Malapel M
    4. Lamkanfi M
    5. Kanneganti TD

    (2010) IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation

    The Journal of Immunology 185:4912–4920.

    https://doi.org/10.4049/jimmunol.1002046

    • PubMed
    • Google Scholar
72. 1. Zhou Z
    2. Treis D
    3. Schubert SC
    4. Harm M
    5. Schatterny J
    6. Hirtz S
    7. Duerr J
    8. Boucher RC
    9. Mall MA

    (2008) Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice

    American Journal of Respiratory and Critical Care Medicine 178:1245–1256.

    https://doi.org/10.1164/rccm.200803-442OC

    • PubMed
    • Google Scholar
73. 1. Zhou Z
    2. Duerr J
    3. Johannesson B
    4. Schubert SC
    5. Treis D
    6. Harm M
    7. Graeber SY
    8. Dalpke A
    9. Schultz C
    10. Mall MA

    (2011) The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease

    Journal of Cystic Fibrosis 10:S172–S182.

    https://doi.org/10.1016/S1569-1993(11)60021-0

    • PubMed
    • Google Scholar
74. 1. Zhu J
    2. Yang Y
    3. Hu SG
    4. Zhang QB
    5. Yu J
    6. Zhang YM

    (2017) T-lymphocyte Kv1.3 channel activation triggers the NLRP3 inflammasome signaling pathway in hypertensive patients

    Experimental and Therapeutic Medicine 14:147–154.

    https://doi.org/10.3892/etm.2017.4490

    • PubMed
    • Google Scholar

Author details

1. Thomas Scambler

   Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

   Contribution

   Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing—original draft, Writing—review and editing

   Contributed equally with

   Heledd H Jarosz-Griffiths

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-2468-0218

2. Heledd H Jarosz-Griffiths

   1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
   2. Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom
   3. Leeds Cystic Fibrosis Trust Strategic Research Centre, University of Leeds, Leeds, United Kingdom

   Contribution

   Data curation, Formal analysis, Investigation, Methodology, Writing—original draft, Writing—review and editing

   Contributed equally with

   Thomas Scambler

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-5154-4815

3. Samuel Lara-Reyna

   1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
   2. Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom

   Contribution

   Data curation, Formal analysis

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-9986-5279

4. Shelly Pathak

   Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

   Contribution

   Data curation, Formal analysis

   Competing interests

   No competing interests declared

5. Chi Wong

   1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
   2. Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom
   3. Leeds Cystic Fibrosis Trust Strategic Research Centre, University of Leeds, Leeds, United Kingdom

   Contribution

   Data curation, Formal analysis, Project administration

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-2108-1615

6. Jonathan Holbrook

   1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
   2. Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom
   3. Leeds Cystic Fibrosis Trust Strategic Research Centre, University of Leeds, Leeds, United Kingdom

   Contribution

   Writing—review and editing

   Competing interests

   No competing interests declared

7. Fabio Martinon

   1. Leeds Cystic Fibrosis Trust Strategic Research Centre, University of Leeds, Leeds, United Kingdom
   2. Department of Biochemistry, University of Lausanne, Lausanne, Switzerland

   Contribution

   Conceptualization, Supervision, Investigation, Visualization, Writing—review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-6969-822X

8. Sinisa Savic

   1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
   2. Leeds Cystic Fibrosis Trust Strategic Research Centre, University of Leeds, Leeds, United Kingdom
   3. Department of Clinical Immunology and Allergy, St James’s University Hospital, Leeds, United Kingdom

   Contribution

   Conceptualization, Investigation, Visualization, Writing—original draft, Writing—review and editing

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-7910-0554

9. Daniel Peckham

   1. Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom
   2. Leeds Cystic Fibrosis Trust Strategic Research Centre, University of Leeds, Leeds, United Kingdom
   3. Adult Cystic Fibrosis Unit, St James’ University Hospital, Leeds, United Kingdom

   Contribution

   Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Visualization, Writing—original draft, Project administration, Writing—review and editing

   Contributed equally with

   Michael F McDermott

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-7723-1868

10. Michael F McDermott

    1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
    2. Leeds Cystic Fibrosis Trust Strategic Research Centre, University of Leeds, Leeds, United Kingdom

    Contribution

    Conceptualization, Resources, Funding acquisition, Investigation, Writing—original draft, Project administration, Writing—review and editing

    Contributed equally with

    Daniel Peckham

    For correspondence

    M.McDermott@leeds.ac.uk

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-1015-0745

• 2,970

  views

• 556

  downloads

• 82

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.